

ASX RELEASE

Volpara February Newsletter

Wellington, NZ, 27 February 2018: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening using artificial intelligence (AI), is pleased to provide investors with its February Investor Newsletter.

The eNewsletter outlines the Company's recent activities and upcoming events, including:

- Record quarterly sales performance and highlights of the 4C
- UK NHS programme implements VolparaDensity in new trial
- Signing of Wesley Breast Clinic
- Video interview with Imaging Associates Radiologist and Clinical Director Dr Daniel Lee discussing the positive impact of VolparaEnterprise software
- A recent study by the University of Manchester supporting Volpara technology
- The Company's most recent blog by CEO, Dr Ralph Highnam on the transition from capital sales to a SaaS business model
- Free registration to the Australian Healthcare Week Expo Sydney
- Recent Volpara and breast density media coverage
- Upcoming events

The Investor Newsletter can be viewed here: <http://bit.ly/2CKolBr>

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722